BioMarin
drug for
genetic disorder succeeds in
late-stage study
March 21 (Reuters) -
BioMarin Pharmaceutical Inc said preliminary data showed its experimental
drug met the main goal of reducing blood phenylalanine in patients with a
genetic disorder, in a
late-stage study.
